Drug Trial Radar · NCT06742853
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Dec 20, 2024
Primary completion
Oct 29, 2025
Study completion Oct 29, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
Conditions
- Dyslipidemia
Interventions
AZD0780Drug
AZD0780 tablet will be administered orally.
EzetimibeDrug
Ezetimibe tablet will be administered orally.
RosuvastatinDrug
Rosuvastatin tablet will be administered orally.
Bempedoic AcidDrug
Bempedoic Acid tablet will be administered orally.
PlaceboDrug
Placebo will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in direct Low-density Lipsprotein Cholesterol (LDL-C)Time frame: Week 4
- Number of participants with adverse eventsTime frame: From screening (Day -56 to -29) to 14 Weeks
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Glendale, California
Research Site
Brooklyn, Maryland
Research Site
Harrow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.